[新型喜树碱衍生物CPT-11在肾包膜下移植瘤模型中的临床前评价]
[Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
作者信息
Wang Y, Inoue K, Shibata H, Itoh Y, Chen S C, Ogawa M
出版信息
Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1264-7.
CPT-11 is a new derivative of camptothecin, a plant alkaloid developed in Japan. We investigated the antitumor activity of CPT-11 on the subrenal capsule assay by using 39 tumor samples from patients with various tumors. The overall chemosensitivity rate of CPT-11 was 44% and the mean tumor growth inhibition rate was 44% in all the tumors. In 18 ovarian cancer cases, the chemosensitivity rate was 56% and the mean tumor growth inhibition rate was 46%. The antitumor activity obtained by CPT-11 is comparable to that of adriamycin, cyclophosphamide and 5-fluorouracil in the same assay system. Based upon these results, CPT-11 is considered to be a good candidate for clinical trials.
CPT - 11是喜树碱的一种新衍生物，喜树碱是一种在日本研发的植物生物碱。我们使用来自患有各种肿瘤患者的39个肿瘤样本，通过肾包膜下测定法研究了CPT - 11的抗肿瘤活性。在所有肿瘤中，CPT - 11的总体化学敏感性率为44%，平均肿瘤生长抑制率为44%。在18例卵巢癌病例中，化学敏感性率为56%，平均肿瘤生长抑制率为46%。在相同的测定系统中，CPT - 11获得的抗肿瘤活性与阿霉素、环磷酰胺和5 - 氟尿嘧啶相当。基于这些结果，CPT - 11被认为是临床试验的良好候选药物。
Zotero 插件